Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Maze Therapeutics (MAZE) Equity Ratio (2024 - 2026)

Maze Therapeutics' Equity Ratio history spans 3 years, with the latest figure at 0.81 for Q1 2026.

  • On a quarterly basis, Equity Ratio fell 7.22% to 0.81 in Q1 2026 year-over-year; TTM through Mar 2026 was 0.81, a 7.22% decrease, with the full-year FY2025 number at 0.89, up 169.09% from a year prior.
  • Equity Ratio hit 0.81 in Q1 2026 for Maze Therapeutics, down from 0.89 in the prior quarter.
  • Over the last five years, Equity Ratio for MAZE hit a ceiling of 0.9 in Q3 2025 and a floor of 1.29 in Q4 2024.
  • Historically, Equity Ratio has averaged 0.51 across 3 years, with a median of 0.87 in 2025.
  • Biggest five-year swings in Equity Ratio: surged 169.09% in 2025 and later dropped 7.22% in 2026.
  • Tracing MAZE's Equity Ratio over 3 years: stood at 1.29 in 2024, then soared by 169.09% to 0.89 in 2025, then dropped by 8.92% to 0.81 in 2026.
  • Business Quant data shows Equity Ratio for MAZE at 0.81 in Q1 2026, 0.89 in Q4 2025, and 0.9 in Q3 2025.